CA SB852

Establishes the California Affordable Drug Manufacturing Act of 2020, requiring the California Health and Human Services Agency (CHHSA) to enter into partnerships to produce or distribute generic prescription drugs and at least one form of insulin at affordable prices.

Requires CHHSA to prioritize generic drugs that address market failures, reduce costs to patients, increase competition, and improve access, considering factors such as FDA fees, production costs, and research and development expenses when setting prices.

Mandates CHHSA to consult with public and private purchasers including Medi-Cal, health insurers, hospitals, pharmacy benefit managers, and the Public Employees' Retirement System to identify targeted drugs and procurement volumes.

Requires CHHSA to submit a report to the Legislature by July 1, 2022, describing the status of targeted drugs and analyzing impacts on competition, access, and costs, and by July 1, 2023, assessing the feasibility of directly manufacturing generic drugs.

Exempts all nonpublic information and documents related to the program from disclosure under the California Public Records Act to protect proprietary and confidential information regarding manufacturer costs, drug pricing, and rebates.